Cargando…

TIL therapy and anti-CTLA4: can they co-exist?

Detalles Bibliográficos
Autores principales:	Forget, Marie-Andrée, Haymaker, Cara, Amaria, Rodabe N., Bernatchez, Chantale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343756/ https://www.ncbi.nlm.nih.gov/pubmed/30713594 http://dx.doi.org/10.18632/oncotarget.26509

Ejemplares similares

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jieqing, et al.
Publicado: (2014)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells
por: Haymaker, Cara, et al.
Publicado: (2013)

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
por: Parra, Edwin R., et al.
Publicado: (2017)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2016)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity
por: Forget, Marie-Andrée, et al.
Publicado: (2015)

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
por: Haymaker, Cara L, et al.
Publicado: (2015)

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
por: Im, Jin S., et al.
Publicado: (2016)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Molecular and immune heterogeneity in synchronous melanoma metastases
por: Reuben, Alexandre, et al.
Publicado: (2015)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs
por: Alabanza, Leah, et al.
Publicado: (2014)

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017)

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
por: Fix, Samantha M, et al.
Publicado: (2022)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023)

Correlation between cancer stem cells (CSCs) and tumor-infiltrating lymphocytes (TILs): do TILs interact with CSCs in non-small cell lung cancer?
por: Ling, Min, et al.
Publicado: (2020)

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
por: Uemura, Marc, et al.
Publicado: (2016)

Back from the dead: TIL apoptosis in cancer immune evasion
por: Horton, Brendan L, et al.
Publicado: (2018)

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
por: Punt, Simone, et al.
Publicado: (2020)

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Community ophthalmology - Can excellence, efficiency, and equity co-exist?
por: Honavar, Santosh G
Publicado: (2020)

New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy
por: Waight, Jeremy D., et al.
Publicado: (2018)

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy
por: Forget, Marie-Andrée, et al.
Publicado: (2013)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer
por: Ju, Xiaoli, et al.
Publicado: (2017)

Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018)

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer
por: Bufe, Sandra, et al.
Publicado: (2022)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pjkth1quh0f14ev7u2uodt1vte